Walnut Creek, CA

Allergy and Asthma Clinical Research

Hereditary Angioedemas

Angioedema

Hypersensitivity

Chronic Obstructive Pulmonary Disease

Lung Diseases

Sinusitis

Peanut Hypersensitivity

Asthma

Obstructive Lung Diseases

Lanadelumab

Indacaterol

Reslizumab

Rocatinlimab

Ligelizumab

Shire

Amgen

CSL Behring

Novartis

Takeda

Joshua S. Jacobs

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Allergy and Asthma Clinical Research | Walnut Creek, CA

Site insights

Work at this site?

Active trials

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Trial sponsors